Future Planet Capital

– Vaccitech Ltd from Oxford develops a proprietary platform to treat and prevent infectious diseases and cancer.
– The company raised $168m in Series B funding.
– The round was led by M&G Investment Management and attracted new investor Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others.
– The new investment will be used to develop the company’s pipeline of product candidates targeting infectious disease (including MERS coronavirus and Herpes Zoster) and cancer (including non-small cell lung cancer).

– Future Planet Capital invests in a $168m Series B financing announced today by Vaccitech Ltd.
– Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation.
– As part of the Series B financing, $43m in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168m before expenses.
– Future Planet Capital is a London-based investment firm focused on venture capital and private equity investments in early stage life sciences companies.